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OBJECTIVES The aim of the present study was to evaluate the influence of amiodarone on neurochemical
parameters of sympathetic nervous activity in patients with congestive heart failure.
BACKGROUND Unlike most antiarrhythmic agents, amiodarone has been shown to exert a beneficial effect on
survival in some studies of patients with congestive heart failure. The pharmacology of this
agent is complex, and as such, the mode of its action is unclear in humans. Some experimental
studies suggest that amiodarone exerts a sympatholytic effect.
METHODS To evaluate the effect of amiodarone on sympathetic nervous activity, we measured the total
systemic and cardiac norepinephrine (NE) spillover rate by isotope dilution in 58 patients
with severe heart failure (left ventricular ejection fraction 20 6 1%), 22 of whom were
receiving chronic amiodarone treatment. Release rates for dihydroxyphenylalanine (DOPA, a
precursor of NE), and endogenous and radiolabeled dihydroxyphenylglycol (DHPG and
3H-DHPG, intraneuronal metabolites of NE and 3H-NE, respectively) were also determined
to assess sympathetic neuronal integrity.
RESULTS Amiodarone-treated patients had significantly lower cardiac spillover rates for NE (42%, p 5
0.001), DOPA (74%, p , 0.001), DHPG (44%, p , 0.01) and 3H-DHPG (51%, p , 0.01)
than those patients not treated with amiodarone. Hemodynamic assessment of amiodarone-
treated patients revealed higher cardiac output (4.4 6 0.2 vs. 3.7 6 0.2 liters/min, p , 0.01),
and slightly lower pulmonary capillary wedge pressure (18 6 2 vs. 22 6 1, p 5 NS) than in
untreated patients. After correction for the potential confounding effect of hemodynamic
differences, amiodarone-treated patients continued to demonstrate significantly lower spill-
over rates of NE, DOPA and DHPG from the heart.
CONCLUSIONS These data indicate that amiodarone may exert beneficial effects on the failing human heart
through a sympatholytic process, and this action appears to be relatively cardioselective. (J
Am Coll Cardiol 1999;33:1553–9) © 1999 by the American College of Cardiology
Although the use of angiotensin-converting enzyme inhib-
itors (1,2) has significantly reduced total heart failure (HF)
mortality and recent studies of third-generation beta-
adrenergic blocking agents show similar promise (3), sudden
death due to ventricular tachyarrhythmia remains a major
clinical issue in the management of HF patients. Accord-
ingly, numerous studies have been performed to identify
those patients at greatest risk of arrhythmic death, with the
aim of instituting preventative therapy. Unfortunately, the
vast majority of antiarrhythmic agents have either been
ineffective or proarrhythmic in HF patients (4).
To date, amiodarone is the only antiarrhythmic agent
that has been shown to exert a beneficial effect on survival in
HF patients (5), although not all studies have supported this
observation (6). In conjunction, amiodarone has been shown to
be particularly effective in suppressing ventricular ectopy and
ventricular arrhythmias in a variety of clinical circumstances
(7). Despite the increasing use of amiodarone, the precise
means by which it exerts its antiarrhythmic actions remains
uncertain. Although classified as a class III antiarrhythmic
agent by virtue of its effects on the delayed rectifier current
and consequently action potential duration, amiodarone
exerts a wide range of actions including blockade of inward
sodium and calcium currents (8,9) and alpha- and beta-
adrenoceptor antagonism (10). In recent studies from our
group (11), the acute intravenous administration of amio-
darone in rats reduced the rate of norepinephrine release
from the heart dose-dependently during nerve stimulation.
The demonstration of a potential sympatholytic action of
amiodarone therefore could have particular significance,
given that: i) the cardiac norepinephrine spillover rate is
markedly increased in the failing human heart (12–14), and
is strongly associated with an adverse prognosis (15); and
ii) beta-blocking drugs exert beneficial effects on both
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symptoms and outcome in patients with heart failure (3,16).
Within this context, the aim of this study was to evaluate the
effects of long-term amiodarone therapy on total systemic
and cardiac sympathetic function in human heart failure.
METHODS
Study patients. Fifty-eight consecutive patients with mod-
erate to severe heart failure who presented to our institution
for heart failure management and/or transplant evaluation
participated in this study. The mean left ventricular ejection
for this patient group was 20 6 1%. At the time of inclusion
in this study, 22 patients were receiving chronic (.1 month)
amiodarone therapy, initiated at the discretion of their
treating physicians. In 16 of these patients heart failure was
the presenting symptom and amiodarone was initiated on
the basis of Holter monitor findings. In the remaining six
patients, symptomatic ventricular arrhythmias were either
the presenting symptom (with subsequent demonstration of
left ventricular dysfunction) or were coexistent with symp-
tomatic heart failure. Specific characteristics of the patient
population grouped according to treatment with amioda-
rone are presented in Table 1. All patients gave written
informed consent, and the study was performed with the
approval of the Alfred Hospital Ethics Review Committee.
Catheterization protocol. All patients underwent invasive
hemodynamic testing and neurochemical evaluation of total
systemic and cardiac sympathetic function. All studies were
performed in the morning, and medications were continued
in all patients to avoid hemodynamic instability and poten-
tial exaggeration of sympathoexcitation. A thermodilution
catheter (7-F Arrow, Arrow International) was inserted
percutaneously under local anesthesia via the right internal
jugular vein, for the determination of pulmonary arterial
pressures, pulmonary capillary wedge pressure and cardiac
output. The cardiac output was determined from the aver-
age of three cardiac output measurements that varied by less
than 10%. Arterial blood pressure was determined invasively
via a radial arterial cannula.
At the completion of the hemodynamic assessment a
coronary sinus thermodilution catheter (Webster Laborato-
ries, California) was positioned in the coronary sinus under
fluoroscopic control. The tip of the thermodilution catheter
was confirmed to lie at least 2 cm proximal to the coronary
sinus orifice in all cases by injection of radiographic contrast.
The coronary sinus blood flow was subsequently determined
as previously described (17), and simultaneous arterial and
coronary sinus blood sampling was performed. Coronary
sinus plasma flow was calculated after determination of each
patient’s hematocrit.
Radiotracer assessment of sympathetic function. A neu-
rochemical approach to measuring total systemic and car-
diac sympathetic activity and neuronal biochemical integrity
was employed as previously described by our group. In brief,
radiolabeled L-[7-3H]-norepinephrine was continuously in-
fused (0.5 to 1 mCi/min) through a peripheral vein, to
achieve a steady-state plasma concentration.
The rate of appearance rate of norepinephrine in plasma
was measured as an indirect index of “global” sympathetic
nervous activity, and calculated as the ratio of the infusion
rate for 3H-labeled norepinephrine to the plasma-specific
activity of norepinephrine in plasma, as previously described
(18,19).
A more extensive assessment of cardiac sympathetic
nervous activity and neuronal function was performed by
measuring the transcardiac spillover of norepinephrine, its
precursor dihydroxyphenylalanine (DOPA) and dihydroxy-
phenylglycol (DHPG), the intraneuronal metabolite of
norepinephrine. The regional spillover rate for norepineph-
rine was computed using a modified Fick equation, which
includes a correction for the extraction of norepinephrine
across the heart (19,20). The cardiac spillover rates for
DOPA and DHPG were calculated as previously described
(13).
Biochemical assays. Upon collection, blood samples were
immediately transferred to ice-chilled tubes containing eth-
ylene glycol tetraacetic acid and reduced glutathione. Sam-
ples were stored on ice and subsequently separated by
centrifugation at 4°C. Plasma samples were stored at 270°C
until assay. Norepinephrine, DOPA and DHPG concen-
trations were determined by high performance liquid chro-
matography with electrochemical detection (21). The
Abbreviations and Acronyms
DHPG 5 dihydroxyphenylglycol
DOPA 5 dihydroxyphenylalanine
HF 5 heart failure
Table 1. Demographic and Hemodynamic Data
No
Amiodarone Amiodarone
n 36 22
Age (yr) 51 6 2 51 6 2
CAD/DCM (n) 17/19 11/11
LVEF (%) 19.2 6 1.2 21.0 6 1.7
NYHA class 2.8 6 0.1 2.8 6 0.1
Diuretics (n) 36 21
ACE inhibitors (n) 36 21
Digoxin (n) 31 16
MAP (mm Hg) 79 6 2 81 6 2
HR (beats/min) 87 6 3 73 6 3*
Cardiac output (liters/min) 3.7 6 0.2 4.4 6 0.2*
Mean PAP (mm Hg) 30 6 2 26 6 2
PCWP (mm Hg) 22 6 1 18 6 2†
*p , 0.01. †p 5 0.06.
ACE 5 angiotensin-converting enzyme; CAD 5 coronary artery disease;
DCM 5 dilated (nonischemic) cardiomyopathy; LVEF 5 left ventricular ejection
fraction; HR 5 heart rate; MAP 5 mean arterial pressure; NYHA 5 New York
Heart Association; PAP 5 pulmonary artery pressure; PCWP 5 pulmonary capillary
wedge pressure.
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plasma-specific activity of tritiated norepinephrine and di-
hydroxyphenylglycol was determined by performing timed
collections of the detector cell eluant. Radioactivity was
measured by liquid scintillation spectroscopy.
Statistical methods. Data are presented as the mean 6
standard error of the mean. Where normally distributed,
between-group comparisons were performed by an unpaired
Student t test. Data that were not normally distributed were
compared using the Wilcoxon rank-sum test. Between-
groups comparison of the frequency of categorical variables
was performed using the chi-square test. Relations between
continuous variables were examined using the least squares
method of linear regression. Analysis of the entire patient
population revealed significantly milder hemodynamic im-
pairment in the amiodarone-treated group. To avoid this
observation as a confounding factor, a secondary compari-
son between amiodarone-treated and -untreated individuals
was performed using a case-matching approach, where
individuals were matched according to mean pulmonary
artery pressure, which we have previously reported as being
the hemodynamic parameter that correlates most signifi-
cantly with cardiac norepinephrine spillover (13). The null
hypothesis was rejected when the p value was ,0.05.
RESULTS
The demographic and hemodynamic data are detailed in
Table 1, classified according to treatment with or without
amiodarone.
Neurochemical indices of total systemic and cardiac
sympathetic activity. The arterial concentration of norepi-
nephrine was elevated in this heart failure patient group, as
previously described (15,22), but similar between patients
according to amiodarone treatment (treated vs. untreated:
2.6 6 0.3 vs. 3.3 6 0.3 nmol/liter, p 5 NS). Similarly, the
total body spillover rate for norepinephrine to plasma was
not significantly different between amiodarone-treated pa-
tients and their nontreated counterparts (5.6 6 0.4 vs. 4.6 6
0.4 nmol/min, p 5 NS). The arterial concentration of
DOPA, the norepinephrine precursor, was similar in treated
and untreated patients (10.8 6 0.9 vs. 9.9 6 0.6 nmol/liter,
p 5 NS). The arterial concentration of DHPG, the major
intraneuronal metabolite of norepinephrine, was also similar
among the two patient groups (treated vs. untreated: 6.2 6
0.4 vs. 7.6 6 0.4 nmol/L).
Despite the lack of apparent effect of amiodarone on
indices of total systemic sympathetic activity, significant
differences in the neurochemical markers of cardiac sympa-
thetic neuronal function were evident (Fig. 1). The cardiac
norepinephrine spillover rate was 42% lower in those pa-
tients treated with amiodarone (248 6 22 vs. 433 6
50 pmol/min, p 5 0.001). There was also lower cardiac
release rate for DOPA in amiodarone-treated patients
(55 6 23 vs. 211 6 29 pmol/min, p , 0.001). The cardiac
release rate for DHPG and 3H-DHPG was also signifi-
cantly lower in amiodarone-treated patients (Fig. 1). The
fractional extraction of tracer tritiated norepinephrine was
not significantly different between treated and untreated
groups (57 6 4 vs. 56 6 2%, p 5 NS), and there was no
between-group differences for coronary sinus blood flow
(189 6 14 vs. 224 6 15 ml/min).
Hemodynamic profiles, and influence on sympathetic
activity. Although the group of patients treated with ami-
odarone had a similar mean left ventricular ejection fraction
to those not receiving amiodarone, they were characterized
by a higher cardiac output (Table 1). Amiodarone patients
also had a nonsignificant trend toward lower pulmonary
arterial and wedge pressures. The heart rate of amiodarone-
treated patients was significantly lower than that in their
untreated counterparts. The mean arterial pressure was not
different between the two groups.
In view of a previous report from our group that demon-
strated a strong, positive relationship between pulmonary
arterial pressure and cardiac sympathetic activity (13), we
compared the cardiac norepinephrine spillover between
groups, by matching the mean pulmonary artery pressure of
the 22 amiodarone-treated patients with 22 nontreated
patients (Table 2). In this analysis, the cardiac spillover rate
for norepinephrine, DOPA and DHPG continued to be
significantly lower in patients treated with amiodarone.
After adjustment in this manner, cardiac output continued
to be significantly higher in amiodarone-treated patients. In
Figure 1. Bar graphs representing the differences in cardiac spill-
over rates for norepinephrine (NE SR), dihydroxyphenylalanine
(DOPA SR), dihydroxyphenylglycol (DHPG SR) and tritium-
labeled dihydroxyphenylglycol (3H DHPG SR), for patients not
treated with amiodarone (A2) and those treated with amiodarone
(A1). *p , 0.05, **p , 0.01, ***p , 0.001.
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patients not treated with amiodarone, a weakly significant
correlation between cardiac output and cardiac norepin-
ephrine spillover rate could be demonstrated (r 5 20.35,
p 5 0.04), but no relationship between cardiac output and
DOPA or DHPG spillover from the heart was evident. In
a separate case-matching analysis, patients in the two
study groups were matched according to cardiac output
(Table 3). In this analysis, a major influence of amioda-
rone on sympathetic neuronal biochemical integrity was
still evident.
Mechanism of action. To explore the potential mecha-
nism for the effect of amiodarone on cardiac sympathetic
neuronal function, we examined the relationship between
the cardiac spillover rates for DOPA, norepinephrine and
DHPG as an index of sympathetic neuronal biochemical
integrity. In amiodarone-treated patients the ratio of cardiac
DOPA spillover to cardiac norepinephrine spillover was
significantly lower than in nontreated patients (Fig. 2). In
contrast, the ratio of the cardiac spillover rates for both
DHPG and 3H-DHPG and norepinephrine were not
significantly different among patient groups (Fig. 2).
DISCUSSION
In the current study we examined the influence of chronic
amiodarone therapy on cardiac and total systemic sympa-
thetic activity using a neurochemical approach established
by our group (18,19). The major finding was that amioda-
rone in clinically relevant doses potently reduced the spill-
over of norepinephrine to plasma from the heart, in patients
with severely depressed left ventricular function.
Sympathetic nervous system in heart failure. Congestive
cardiac failure has been well characterized as a syndrome
marked by neurohumoral activation. Of paramount impor-
tance, activation of the sympathetic nervous system has been
shown to be associated with an adverse prognosis, based
upon measurements of the peripheral plasma norepineph-
rine concentration and, more recently, the rate of norepi-
nephrine release from the failing heart specifically (15,22).
The spatial pattern of sympathoexcitation that occurs in
heart failure is not homogeneous, and appears to be most
marked in the heart (12,13). Further, increased activity of
the cardiac sympathetic efferent fibers may even occur in
Table 2. Hemodynamic and Neurochemical Profile in Patients Matched by Pulmonary Artery
Pressure
No Amiodarone
(n 5 22)
Amiodarone
(n 5 22)
p
Value
MAP (mm Hg) 80 6 2 81 6 2 NS
HR (beats/min) 87 6 4 73 6 3 0.01
Cardiac output (liters/min) 3.8 6 0.2 4.4 6 0.2 , 0.05
Mean PAP (mm Hg) 26 6 2 26 6 2 NS
PCWP (mm Hg) 18 6 2 18 6 2 NS
LVEF (%) 21 6 2 21 6 2 NS
Cardiac NE SR (pmol/min) 363 6 49 248 6 22 , 0.05
Cardiac DOPA SR (pmol/min) 201 6 34 59 6 25 , 0.01
Cardiac DHPG SR (pmol/min) 743 6 126 413 6 38 , 0.05
Cardiac 3H-DHPG SR (dpm/min) 7,645 6 1,208 4,013 6 614 , 0.05
DHPG 5 dihydroxyphenylglycol; DOPA 5 dihydroxyphenylalanine; HR 5 heart rate; LVEF 5 left ventricular ejection
fraction; MAP 5 mean arterial pressure; NE 5 norepinephrine; PAP 5 pulmonary artery pressure; PCWP 5 pulmonary
capillary wedge pressure; SR 5 spillover rate.
Table 3. Hemodynamic and Neurochemical Profile in Patients Matched by Cardiac Output
No Amiodarone
(n 5 20)
Amiodarone
(n 5 20)
p
Value
MAP (mm Hg) 80 6 2 81 6 2 NS
HR (beats/min) 81 6 3 75 6 3 NS
Cardiac output (liters/min) 4.1 6 0.2 4.2 6 0.2 NS
Mean PAP (mm Hg) 27 6 2 30 6 3 NS
PCWP (mm Hg) 18 6 2 22 6 2 NS
LVEF (%) 19 6 1 19 6 1 NS
Cardiac NE SR (pmol/min) 408 6 60 253 6 24 , 0.05
Cardiac DOPA SR (pmol/min) 199 6 41 39 6 21 , 0.01
Cardiac DHPG SR (pmol/min) 779 6 134 388 6 37 , 0.05
Cardiac 3H-DHPG SR (dpm/min) 7,485 6 1,253 3,897 6 651 , 0.05
Abbreviations as in Table 2.
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isolation in mild heart failure, as reported recently by
Rundqvist and colleagues (14). The potential pathophysio-
logic mechanisms by which increased cardiac sympathetic
nervous activity translates into adverse clinical end points
are numerous, and include: i) facilitation of ventricular
arrhythmia development, ii) exacerbation of underlying
myocardial ischemia, and iii) alteration of myocardial struc-
ture, including fibrosis and myocyte necrosis (23,24), in
addition to the potential effects of down-regulation of
beta-adrenoreceptors and their second messenger signaling
effector pathways (25,26).
The clinical importance of modulating the sympathoad-
renergic neuroeffector pathway in patients with heart failure
has been highlighted by the recent multicenter carvedilol
study (3). Although this study showed a favorable effect on
both morbidity and mortality, the mechanism(s) by which
carvedilol exerts this action is not clear. Gilbert and col-
leagues recently demonstrated that carvedilol reduced the
concentration of norepinephrine in the coronary sinus,
whereas metoprolol led to an increase, and carvedilol ther-
apy was associated with a somewhat more favorable effect on
left ventricular function (27). These data might therefore
suggest that the antiadrenergic influence of carvedilol is a
key component of its beneficial clinical actions.
Sympatholytic action of amiodarone in the failing heart.
In the current study we observed a 42% lower cardiac
norepinephrine spillover rate in patients chronically treated
with amiodarone. In a recent study from our group, the
acute administration of intravenous amiodarone in rats was
associated with a significant reduction in the cardiac nor-
epinephrine overflow rate during direct sympathetic nerve
stimulation (11). In this study, however, chronic amioda-
rone dosing had no effect on cardiac norepinephrine release.
Our findings are also consistent with previous data which
demonstrate that amiodarone attenuates cardiac responses
to sympathetic stimulation through mechanism(s) that are
not dependent on adrenoceptor blockade (28).
The rate of spillover of norepinephrine to plasma from
the sympathetic neuroeffector junction is dependent on a
number of factors that include the rate of neurotransmitter
release (determined by the synthesis rate, vesicular storage
and degranulation and nerve firing rate), the rate of neuro-
nal reuptake and the influence of other factors including the
presence of diffusion barriers between the synaptic cleft and
plasma (19). In the current study, amiodarone therapy was
associated with a marked reduction in the transcardiac
release of the norepinephrine precursor DOPA, suggesting
that the sympatholytic actions of amiodarone might be
mediated by reduced norepinephrine synthesis. In prelimi-
nary studies, we examined myocardial tyrosine hydroxylase
messenger ribonucleic acid expression in explanted failing
tissue, but were unable to demonstrate an effect of amioda-
rone, albeit in a small number of patients (unpublished
observations). This finding, however, does not exclude an
effect of amiodarone on tyrosine hydroxylase enzymatic
activity, which may be increased under certain conditions by
phosphorylation (29). The apparently lower rates of trans-
cardiac DOPA and norepinephrine spillover could, poten-
tially, also be explained by lower rates of sympathetic nerve
firing in the amiodarone-treated patients (30), although in
this situation a greater reduction in DOPA than norepi-
nephrine spillover would not be expected. In our study,
amiodarone-treated patients were somewhat less hemody-
namically compromised than nontreated patients, albeit
with similar left ventricular ejection fractions. On the basis
of previous studies which demonstrated that both cardiac
norepinephrine spillover and muscle sympathetic nerve
activity were positively correlated with pulmonary arterial
pressures (13,31), we attempted to correct for between-
group hemodynamic differences as a potential confounding
factor. In this analysis, cardiac norepinephrine spillover
remained significantly lower, suggesting that the effect of
amiodarone was not likely to be mediated by an effect on
nerve firing rate per se.
Norepinephrine spillover to plasma may also be influ-
enced by factors affecting the neuronal reuptake of norepi-
nephrine from the synaptic cleft (32). In the current study
we did not observe any difference in the transcardiac
extraction of tracer norepinephrine across the heart. Al-
though we also observed lower rates of transcardiac spillover
Figure 2. Bar graph comparing the ratios of transcardiac spillover
rates for dihydroxyphenylalanine to norepinephrine (DOPA:NE
SR), dihydroxyphenylglycol to norepinephrine (DHPG:NE SR)
and tritium-labeled dihydroxyphenylglycol to norepinephrine (3H
DHPG:NE SR) for nontreated (A2) and treated patients (A1).
**p , 0.05.
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for both unlabeled and radiolabeled DHPG, these were in
direct proportion to the prevailing norepinephrine spillover
rate, suggesting that the actions of amiodarone were not
mediated by an effect on neuronal reuptake or vesicular
storage. This finding is in contrast with the findings of Du
et al. (11), who observed a reserpine-like action of acute
intravenous amiodarone in rats, as reflected by a dose-
dependent increase in cardiac DHPG overflow.
In contrast to the apparent influence of amiodarone on
cardiac sympathetic neuronal function, we could not detect
any effect upon indices of total systemic sympathetic activ-
ity. Specifically, the total body spillover rate for norepineph-
rine was similar for both amiodarone-treated and untreated
patients. Similarly, there were no apparent differences in the
arterial concentration of DOPA, DHPG or 3H-DHPG.
These findings suggest that the sympatholytic action of
amiodarone may be relatively cardiac-specific, although we
did not specifically measure the norepinephrine spillover
rate for other organs, such as the kidney. One potential
explanation for the apparently cardioselective nature of
amiodarone could relate to the fact that sympathetic nervous
activation occurs earliest and is most prominent in the heart
in congestive cardiac failure (14), and that a sympatholytic
action would be most readily detected in an organ receiving
high sympathetic efferent input. This hypothesis may ex-
plain, in part, the apparently contradictory results of the
GESICA and CHF-STAT studies of the effect of amioda-
rone on survival in heart failure (5,6). Were the effects of
amiodarone to be most apparent in the setting of high
cardiac sympathetic tone, then it could be anticipated that
the most compromised patients might derive the greatest
benefit. Consistent with this notion, a follow-up study of
the GESICA trial demonstrated that the beneficial effect of
amiodarone was limited to patients with a heart rate
.90/min, and also lower left ventricular ejection fraction
(33). In addition, the mean heart rate of patients in the
GESICA study was higher than that in CHF-STAT (5,6).
Study limitations. A potential limitation of the present
study was its cross-sectional design. We have attempted to
account for the potential confounding effect of hemody-
namics by matching patients according to their pulmonary
arterial pressures, which we have previously shown to be an
important determinant of cardiac sympathetic tone (13,34).
Although the left ventricular ejection fraction was similar
between the two patient groups, amiodarone-treated pa-
tients displayed a significantly higher cardiac output. In this
study, and in a previous study, we found a significant, albeit
relatively weak, relationship between cardiac output and
cardiac norepinephrine spillover rate. However, cardiac
output bore no relationship to either DHPG or DOPA
spillover from the heart, making it unlikely that the
between-group differences were solely due to hemodynamic
differences. Although it is not possible to account for the
hemodynamic differences in the present study, a previous
study did identify a favorable effect of amiodarone on left
ventricular function (6). Based on this observation it is
possible that the amiodarone-treated group may have had
even greater sympathoexcitation before initiation of amio-
darone due to greater hemodynamic compromise. The
observations of Singh et al. (6) also raise the possibility that
the more favorable hemodynamic profile seen in this patient
group could, in part, be a consequence of the antiadrenergic
effect of amiodarone therapy itself, in a manner analogous to
the beneficial effects of long-term beta-adrenoceptor
blocker therapy (27). The magnitude of the differences in
cardiac catecholamine spillover between the groups also
suggests that this was not merely due to differences in
hemodynamic severity. Most notable was the 74% lower
spillover rate for DOPA in amiodarone-treated patients. In
fact, the spillover rate was even lower than that previously
reported in healthy volunteers (13). Our contention that
amiodarone exerts a sympatholytic action is also supported
by a recent observation from our group that the drug exerts
a reserpine-like action in Chinese hamster ovary cells
expressing the vesicular monoamine transporter (35).
In conclusion, the present study demonstrates for the first
time a sympatholytic action of chronic amiodarone therapy
in humans with congestive heart failure. This action appears
to be cardiac specific and may be mediated through an
action upon the biosynthetic pathway for norepinephrine.
The antiarrhythmic effect of amiodarone may therefore be,
in part, due to its antiadrenergic properties. On the basis of
these studies it might be anticipated that a beneficial effect
of amiodarone might be most apparent in patients with high
levels of cardiac sympathetic overactivity, although this
remains unclear.
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